Take charge of your kidney health!
Learn about the APOL1 gene and how it increases your risk of getting chronic kidney disease
Learn about the APOL1 gene and how it increases your risk of getting chronic kidney disease
Learn about the APOL1 gene and how it increases your risk of getting chronic kidney disease
Learn about the APOL1 gene and how it increases your risk of getting chronic kidney disease
Learn about the APOL1 gene and how it increases your risk of getting chronic kidney disease
Learn about the APOL1 gene and how it increases your risk of getting chronic kidney disease
APOL1-Mediated Kidney Disease (AMKD) refers to chronic kidney disease in patients with APOL1 gene variants.
Everyone has a gene called APOL1 or apolipoprotein L1. We each have inherited two copies of the APOL1 gene, one copy from each of our parents.
Some people have changes in the APOL1 gene, called variants or mutations that raise their risk of chronic kidney disease.
People of African ancestry, including those who identify as Black, African American, Caribbean, and/or Latino, who carry these APOL1 gene variants may experience faster loss of kidney function.
The APOL1 gene variants evolved in Western and Central Africa to protect individuals from a disease known as African sleeping sickness. Over time, these same gene variants are now known to increase a person's risk of developing APOL1-Mediated Kidney Disease.
Kidney diseases can show up in different ways. Symptoms for APOL1-Mediated Kidney Disease are similar to other kidney diseases. Common symptoms include:
Some people may have one or more signs or symptoms. Others may not have any until their kidney disease is more advanced. That is why it is important to see a doctor and check your kidney function with simple urine and blood tests.
APOL1-Mediated Kidney Disease currently has no approved treatments. To address this unmet need, Maze is developing an investigational drug called MZE829 as a potential therapy for APOL1-Mediated Kidney Disease.
Along with the help of trusted patient advisors, physicians, and scientists, Maze has launched our 
Study, and is currently looking for individuals to join. To explore potential eligibility for this trial and/or get genetically tested for APOL1, please Contact Us.
Maze is proud to partner with leaders and allies from the APOL1-Mediated Kidney Disease and Black chronic kidney disease (CKD) communities to create a Patient Advisory Committee for our APOL1-Mediated Kidney Disease Program. This committee ensures that the voices of patients are at the center of everything we do. By working together, we focus on making sure our clinical trials are patient centric, and support study access and participation.
Learn more about APOL1-Mediated Kidney Disease through various kidney patient advocacy organizations.
